-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX)
-
-
-
-
-
-
-
Celldex (CLDX) Mentioned as Positive Again at Citron Research
-
-
-
-
-
-
-
Celldex (CLDX) Tops Q2 EPS by 1c
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Celldex Therapeutics (CLDX)
-
-
-
-
-
-
-
Guggenheim on Celldex Therapeutics (CLDX): 'CLDX Remains Leader In The Mast Cell Space'
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on Celldex Therapeutics (CLDX)
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX)
-
414,163 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

